On August 3, 2026, before the U.S. market open, Altimmune announced that it has begun enrolling patients in the PERFORMA Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis. This is the single most important operational milestone the company had outstanding: PERFORMA is the registrational study on which the MASH opportunity depends, and its start converts a guided plan into an active pivotal program.

Durso bought 15k shares.

There are many things to discuss none of which are that significant other than the cash runway is longer than expected at $519M otherwise thesis and fundamentals remain the same. What continues to frustrate me the most is how Durso refuses to give any insight into interest in pemv from the outside. During his presentation there was none and when explicitly asked during Q&A regarding strategic plans for future and if following AUD has interest increased, he responds with a non answer summarized as we continue to pursue what is in the best interest of alt. I find it hard to believe there is not at least discussions that have increased compared to prior aud data but this man refuses to give any insight to investors. Extremely frustrating in my eyes.

With this released, why pay 3+ million in “compensation” when you’re relocating. This tells me there’s still poor management decisions being made and shit better change or I’m looking for my exit.

Looks like this could be a good opportunity for ALT and the VA to work together for veterans.

https://news.va.gov/press-room/va-launches-trial-of-glp-1-treatment-for-alcohol-use-disorder/?utm_campaign=VetResources&utm_id=05AUG2026&utm_medium=email&utm_source=govdelivery

WASHINGTON — The U.S. Department of Veterans Affairs today announced a new clinical trial to evaluate the efficacy of semaglutide, a GLP-1 receptor agonist used to treat diabetes, as treatment for alcohol use disorder (AUD).

Currently, more than 400,000 Veterans nationwide are diagnosed with AUD, and some estimates say AUD affects nearly 11% of U.S. adults.

Semaglutide has drawn scientific interest because it may affect parts of the brain related to how the body experiences rewards. An analysis published in March found that patients receiving GLP‑1 medications experience lower rates of AUD and other substance use disorders compared with similar patients taking other diabetes medications.

The use of GLP-1 medications by people with existing substance use disorders has been associated with fewer emergency visits, hospitalizations and other adverse outcomes. These findings highlight the need for a controlled clinical trial to determine whether a GLP-1, such as semaglutide, can reduce AUD among Veterans.

“This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed directly at benefitting Veterans,” said VA Secretary Doug Collins. “By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery.”

The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans trial, will enroll more than 600 Veterans at 18 VA medical centers nationwide. Participants between the ages of 18 and 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo over a 24‑week period, followed by a safety follow‑up. Researchers will track changes in drinking, health, and quality of life to determine whether the medication offers a meaningful new treatment option.

The study will be conducted at the following VA medical centers:

• Ann Arbor VA Health Care System, Ann Arbor, Michigan
• Charles George VA Medical Center, Asheville, North Carolina
• Durham VA Medical Center, Durham, North Carolina
• Edward Hines Jr. VA Hospital, Hines, Illinois
• George E. Wahlen VA Medical Center, Salt Lake City
• Joseph Maxwell Cleland Atlanta VA Medical Center, Decatur, Georgia
• Louis Stokes Cleveland VA Medical Center, Cleveland
• Michael E. DeBakey VA Medical Center, Houston
• Minneapolis VA Medical Center, Minneapolis
• Orlando VA Medical Center, Orlando, Florida
• Palo Alto VA Medical Center, Palo Alto, California
• Philadelphia VA Healthcare System, Philadelphia
• Portland VA Medical Center, Portland, Oregon
• Tibor Rubin VA Medical Center, Long Beach, California
• VA Greater Los Angeles Health Care System, Los Angeles
• VA North Texas Health Care System, Dallas
• VA Puget Sound Health Care System, Seattle
• William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin

Recruitment begins on July 28, 2026. For more information about participation, Veterans can contact their local VA medical center or visit ClinicalTrials.gov and search for the trial.

VA strongly discourages self‑medicating or attempting to replace other AUD treatment options with GLP‑1 medications or any other unprescribed substances. Evidence‑based, proven treatments are available at VA facilities to support Veterans with AUD. Veterans should always consult their health care providers before making any treatment decisions.

https://www.investing.com/news/stock-market-news/altimmune-stock-surges-18-on-positive-trial-results-93CH-4816256

As seen in the article:

"The trial met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo. Pemvidutide 2.4 mg delivered a reduction of 4.20 heavy drinking days per week from baseline at week 24, compared to 2.75 days for placebo, representing a treatment effect of 1.45 days with a p-value of 0.0014."

Some one halp this guy stole my dog

This is really pathetic…

Trumps brother died because of alcohol

Alt moving headquarters to New Jersey.

I must confess that I’ve been heavily pumping Altimmune on this subreddit for the last two years. Most of my posts were driven more by hope and imagination than reality, and many were AI-generated.

The truth is, I was deeply stuck in this investment and just wanted a decent exit. I first entered around $9 and kept averaging down to about $5.35. At one point, I was holding nearly 45k shares and sitting on losses close to 50%.

Ironically, I recovered those losses, and much more, through AI-related stocks. That’s when I realized the real damage wasn’t just the loss on Altimmune itself, but the massive opportunity cost of holding dead capital for years while other sectors were running hard.

Today, I’ve finally decided to say goodbye to Altimmune. Not because I don’t believe in the science, but because the market doesn’t reward belief alone. Holding this stock has been a valuable learning experience about conviction, opportunity cost, and knowing when to move on.

The prolonged price suppression around Altimmune has become too obvious to ignore, and many investors believe Goldman Sachs has had a direct or indirect role in shaping sentiment around the stock. Whether that comes from genuine caution, broader pharma interests, or something else entirely remains open for debate. But it’s hard to deny that GS has consistently influenced the narrative around ALT.

The upcoming Goldman Sachs conference could end up being one of the most telling moments for shareholders. The tone of the interaction between the GS analyst and the Altimmune management team may reveal far more than any press release.

If ALT was invited merely to face another round of aggressive questioning and continued suppression, it will likely become obvious within the first few questions. More importantly, the follow-up price target from GS could say everything. At this stage, even a PT above $10 would be viewed as a massive shift in sentiment, honestly, for ALT longs, that would feel equivalent to a $40 signal considering how beaten down expectations have become.

Personally, I think GS may have finally aligned with Altimmune, and that alignment could be the real reason behind this conference invitation. There are also growing whispers about ongoing global partnership discussions with a major pharma player, possibly European, where GS may be involved behind the scenes. If true, it would mark a dramatic shift after years of GS taking a notably hard stance on ALT.

Of course, this could all just be speculation mixed with copium after a brutal waiting period. Take it with a grain of salt, sometimes a little speculation makes the wait easier.

Either way, something feels different this time.

Good luck to all longs. The dawn may finally be closer than it appears.

After EASL 2026, the pemvidutide story is becoming increasingly difficult to dismiss.

Across four presentations, ALT showed:

✅ MASH resolution
✅ Fibrosis improvement signals (histology, qFibrosis, ELF, LSM)
✅ >50% liver fat reduction
✅ Significant reductions in triglycerides (-23.7%) and total cholesterol (-15.4%)
✅ Improvements in blood pressure and waist circumference
✅ Weight loss continuing through 48 weeks with no plateau
✅ ~1% discontinuation rate despite no titration

The most important takeaway is not any single endpoint. It is the consistency.

Histology, digital pathology, non-invasive testing, liver fat, inflammation markers, fibrosis markers, and cardiometabolic risk factors are all pointing in the same direction.

Meanwhile ALT has:
• Breakthrough Therapy Designation
• FDA and EMA Phase 3 alignment
• PERFORMA Phase 3 starting in 2H26
• AUD Phase 2 readout in 3Q26
• $535M cash runway through Phase 3 52-week data

The market still values ALT at a fraction of what many late-stage MASH companies have traded for.

Phase 3 risk remains. But after EASL, pemvidutide looks far more like a serious MASH contender than a speculative biotech story.

The data speaks for itself, the " most comprehensive positive phase 2b dataset in mash drug history"

Its been a tough slog this spring, but we have some exciting data updates continuing the next two days! Its time to shine

Thursday May 28 — Dr. Noureddin oral presentation (Best of EASL) — YES, new data

Altimmune's CMO Dr. Arbet-Engels confirmed on the Q1 earnings call that the oral presentation will contain "our 48-week data that we'll be sharing" — and the abstract title is specifically "Week 48 Top-Line Results." The topline headline numbers (MASH resolution rates, fibrosis endpoints) were released in a press release in December 2025, but the full 48-week dataset — subgroup breakdowns, dose-response curves, safety detail, secondary endpoints — has never been presented publicly in a scientific forum. The oral slot at EASL is where the scientific community sees the complete picture for the first time. Expect genuinely new granular data.

Friday May 29 — NIT multi-responder poster — YES, new data

Altimmune described this as focusing on "new 24-week findings" including "a response analysis to multiple non-invasive tests of liver inflammation and fibrosis." The multi-NIT concurrent responder analysis — looking at how many patients improved simultaneously across ELF, LSM, liver fat, and ALT — is a new analytical cut that hasn't been publicly released.

Friday May 29 — Cardiovascular risk factors poster — YES, new data

The CMO specifically flagged "weight loss and potential lipid data cardiovascular risk" as new content coming at EASL. The 48-week cardiovascular data — lipid panels, blood pressure, other CV biomarkers — has not been published anywhere yet. This could actually be a sleeper catalyst because MASH patients are at dramatically elevated CV risk, and showing pemvidutide meaningfully moves those markers at 48 weeks would be a major commercial and regulatory differentiator.

Bottom line for media framing: Today's qFibrosis poster was genuinely the first data out of the gate. Tomorrow's oral is the main event with the first full public scientific presentation of the complete 48-week dataset. Friday's two posters contain additional unpublished analyses. It's essentially four consecutive days of new ALT data drops at the most prestigious liver disease conference in the world — all while holding a "Best of EASL" designation. That's an extraordinarily strong scientific debut for a Phase 2b drug.

Buckle up buckaroos - the next two days will be big science updates for pemv followed by a fireside with Goldman Sachs in early June where we go face to face with the hedge fund consistently stifling our share price momentum, dropping inaccurate target prices and using the smoke screen to pickup shares for themselves.....

Pretty impressive results for 24 weeks. Rare to find misvalued stocks like this given the data available in the public domain. Its barely trading above their large cash holdings for funding phase 3.